These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study. Herrman JP; Simon R; Umans VA; Peerboom PF; Keane D; Rijnierse JJ; Bach D; Kobi P; Kerry R; Close P Eur Heart J; 1995 Nov; 16 Suppl L():56-62. PubMed ID: 8869020 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters. Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073 [TBL] [Abstract][Full Text] [Related]
4. The role of thrombin inhibition during percutaneous coronary intervention. Wittkowsky AK Pharmacotherapy; 2002 Jun; 22(6 Pt 2):97S-104S. PubMed ID: 12064571 [TBL] [Abstract][Full Text] [Related]
5. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. Ip JH; Fuster V; Israel D; Badimon L; Badimon J; Chesebro JH J Am Coll Cardiol; 1991 May; 17(6 Suppl B):77B-88B. PubMed ID: 2016486 [TBL] [Abstract][Full Text] [Related]
6. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. Imura Y; Stassen JM; Collen D J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotics in interventional cardiology: optimizing treatment and strategies. Ischinger TA Am J Cardiol; 1998 Sep; 82(5B):25L-28L. PubMed ID: 9737477 [TBL] [Abstract][Full Text] [Related]
9. The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN; Villarreal-Levy G; Schafer AI Chest; 1995 Nov; 108(5):1409-19. PubMed ID: 7587450 [No Abstract] [Full Text] [Related]
10. Clinical trials of direct thrombin inhibitors during invasive procedures. Hermann JP; Kutryk MJ; Serruys PW Thromb Haemost; 1997 Jul; 78(1):367-76. PubMed ID: 9198181 [No Abstract] [Full Text] [Related]
12. [Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention]. Böger RH; Bode-Böger SM; Alfke H Vasa; 1996; 25(1):21-31. PubMed ID: 8851262 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of adjunctive thrombolytic therapy in percutaneous transluminal coronary angioplasty. Vaitkus PT; Laskey WK J Am Coll Cardiol; 1994 Nov; 24(5):1415-23. PubMed ID: 7930268 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty. Barry WL; Sarembock IJ Cardiol Clin; 1994 Aug; 12(3):517-35. PubMed ID: 7805084 [TBL] [Abstract][Full Text] [Related]
15. Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Markwardt F Semin Thromb Hemost; 2001 Oct; 27(5):523-30. PubMed ID: 11668423 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty. Sakamoto S; Hirase T; Suzuki S; Tsukamoto T; Miki T; Yamada T; Matsuo T Thromb Haemost; 1995 Aug; 74(2):801-2. PubMed ID: 8585029 [No Abstract] [Full Text] [Related]